[EN] GLYT2 MODULATORS<br/>[FR] MODULATEURS DU GLYT2
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2005044810A1
公开(公告)日:2005-05-19
α-, β-, and Ϝ-amino acid derivatives of formula I are disclosed as selective GlyT2 inhibitors for the treatment of central nervous system (CNS) conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic pain. Formula I
Chiral <i>N</i>-Acylethylenediamines as New Modular Ligands for the Catalytic Asymmetric Addition of Alkylzinc Reagents to Aldehydes
作者:Christopher M. Sprout、Christopher T. Seto
DOI:10.1021/jo0347516
日期:2003.10.1
Chiral N-acylethylenediamines represent a new class of modular ligands for the catalytic asymmetric addition of alkylzincreagents to aldehydes. The N-acylethylenediamine moiety serves as a metal binding site, while attached amino acids provide the source of chirality. Three sites of diversity on the ligands were optimized to enhance the enantioselectivity of the catalysts using an iterative optimization
sensitive labeling reagents D/L-FDVDA and D/L-FDLDA for the structural determination of the component aminoacids in peptides. In an LC-MS-based structural study of peptides, these reagents enabled us to detect infinitesimal amounts of aminoacids derived from mild degradative analysis of the samples. Herein, we firstly report the improved LC-MS protocols for the highly sensitive analyses of amino acids
作者:Ronald L Wolin、Hariharan Venkatesan、Liu Tang、Alejandro Santillán、Tristin Barclay、Sandy Wilson、Doo Hyun Lee、Timothy W Lovenberg
DOI:10.1016/j.bmc.2004.05.042
日期:2004.8
alpha-amino acid derivatives were prepared as glycine transport inhibitors and their ability to block the uptake of [(14)C]-glycine in COS7 cells transfected with human glycine transporter-2 (hGlyT-2) was evaluated. An array of substituents at the chiral center was studied and overall, L-phenylalanine was identified as the preferred amino acid residue. Compounds prepared from l-amino acids were more
Process for lowering the viscosity of highly concentrated protein solutions
申请人:ADOCIA
公开号:US20140044708A1
公开(公告)日:2014-02-13
A process of lowering the viscosity of a solution includes preparing a solution comprising a compound of formula I, at a concentration in the final formulation of between 10 and 250 mM, and a protein having at least one antibody fragment whose concentration is between 50 and 350 mg/mL and whose pH is between 5 and 8.
The compound lowers the viscosity of the solution, which is difficult to inject, by a value of at least 15% relative to the viscosity of a solution of at least one protein having at least one antibody fragment of the same concentration and of the same pH not containing the compound.